{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:20:18Z","timestamp":1767903618842,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T00:00:00Z","timestamp":1531440000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/132751\/2017"],"award-info":[{"award-number":["SFRH\/BD\/132751\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto Portugu\u00eas de Oncologia do Porto, E.P.E.","award":["CI-IPOP-17-2015"],"award-info":[{"award-number":["CI-IPOP-17-2015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00428-018-2406-1","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T08:41:18Z","timestamp":1531471278000},"page":"443-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features"],"prefix":"10.1007","volume":"473","author":[{"given":"Catarina","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o","family":"Lobo","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Antunes","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,7,13]]},"reference":[{"issue":"10013","key":"2406_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, Schr\u00f6der F, Tomlins SA, Tannock I, Drake CG, de Bono JS (2016) Prostate cancer. Lancet 387(10013):70\u201382. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)61947-4","journal-title":"Lancet"},{"issue":"1","key":"2406_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21387","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"2406_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/jnci\/94.13.981","volume":"94","author":"R Etzioni","year":"2002","unstructured":"Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94(13):981\u2013990","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2406_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.1995.03520310046028","volume":"273","author":"AL Potosky","year":"1995","unstructured":"Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273(7):548\u2013552","journal-title":"JAMA"},{"issue":"7","key":"2406_CR5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1342::AID-CNCR18>3.0.CO;2-1","volume":"77","author":"RA Stephenson","year":"1996","unstructured":"Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL (1996) The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence\u2014data from the Utah Cancer registry. Cancer 77(7):1342\u20131348. \n                    https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19960401)77:7<1342::AID-CNCR18>3.0.CO;2-1","journal-title":"Cancer"},{"issue":"2","key":"2406_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.4143\/crt.2014.015","volume":"47","author":"I Tsaur","year":"2015","unstructured":"Tsaur I, Noack A, Makarevic J, Oppermann E, Waaga-Gasser AM, Gasser M, Borgmann H, Huesch T, Gust KM, Reiter M, Schilling D, Bartsch G, Haferkamp A, Blaheta RA (2015) CCL2 chemokine as a potential biomarker for prostate cancer: a pilot study. Cancer Res Treat 47(2):306\u2013312. \n                    https:\/\/doi.org\/10.4143\/crt.2014.015","journal-title":"Cancer Res Treat"},{"key":"2406_CR7","doi-asserted-by":"publisher","first-page":"862639","DOI":"10.1155\/2012\/862639","volume":"2012","author":"AB Barqawi","year":"2012","unstructured":"Barqawi AB, Krughoff KJ, Eid K (2012) Current challenges in prostate cancer management and the rationale behind targeted focal therapy. Adv Urol 2012:862639\u2013862637. \n                    https:\/\/doi.org\/10.1155\/2012\/862639","journal-title":"Adv Urol"},{"issue":"1","key":"2406_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/oxfordjournals.epirev.a000780","volume":"23","author":"GJ Miller","year":"2001","unstructured":"Miller GJ, Torkko KC (2001) Natural history of prostate cancer--epidemiologic considerations. Epidemiol Rev 23(1):14\u201318","journal-title":"Epidemiol Rev"},{"issue":"6","key":"2406_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1464-410X.1990.tb14829.x","volume":"65","author":"J Adolfsson","year":"1990","unstructured":"Adolfsson J, R\u00f6nstr\u00f6m L, Carstensen J, L\u00f6whagen T, Hedlund PO (1990) The natural course of low grade, non-metastatic prostatic carcinoma. Br J Urol 65(6):611\u2013614","journal-title":"Br J Urol"},{"issue":"5","key":"2406_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0090-4295(93)90497-X","volume":"41","author":"DG Bostwick","year":"1993","unstructured":"Bostwick DG, Graham SD, Napalkov P, Abrahamsson PA, di Sant'agnese PA, Algaba F, Hoisaeter PA, Lee F, Littrup P, Mostofi FK (1993) Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology 41(5):403\u2013411","journal-title":"Urology"},{"issue":"22","key":"2406_CR11","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1001\/jama.291.22.2713","volume":"291","author":"JE Johansson","year":"2004","unstructured":"Johansson JE, Andr\u00e9n O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO (2004) Natural history of early, localized prostate cancer. JAMA 291(22):2713\u20132719. \n                    https:\/\/doi.org\/10.1001\/jama.291.22.2713","journal-title":"JAMA"},{"issue":"3","key":"2406_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0022-5347(01)63773-X","volume":"159","author":"JJ Bauer","year":"1998","unstructured":"Bauer JJ, Connelly RR, Seterhenn IA, Deausen J, Srivastava S, McLeod DG, Moul JW (1998) Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 159(3):929\u2013933","journal-title":"J Urol"},{"issue":"4","key":"2406_CR13","doi-asserted-by":"publisher","first-page":"165.e111","DOI":"10.1016\/j.urolonc.2015.10.016","volume":"34","author":"A Drivalos","year":"2016","unstructured":"Drivalos A, Chrisofos M, Efstathiou E, Kapranou A, Kollaitis G, Koutlis G, Antoniou N, Karanastasis D, Dimopoulos MA, Bamias A (2016) Expression of \u03b15-integrin, \u03b17-integrin, \u0395-cadherin, and N-cadherin in localized prostate cancer. Urol Oncol 34(4):165.e111\u2013165.e168. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2015.10.016","journal-title":"Urol Oncol"},{"issue":"6","key":"2406_CR14","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC (2010) The American joint committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471\u20131474. \n                    https:\/\/doi.org\/10.1245\/s10434-010-0985-4","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2406_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2007.10.009","volume":"53","author":"H Poppel Van","year":"2008","unstructured":"Van Poppel H, Joniau S (2008) An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 53(2):253\u2013259. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2007.10.009","journal-title":"Eur Urol"},{"issue":"2","key":"2406_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.juro.2007.03.105","volume":"178","author":"O Yossepowitch","year":"2007","unstructured":"Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178(2):493\u2013499; discussion 499. \n                    https:\/\/doi.org\/10.1016\/j.juro.2007.03.105","journal-title":"J Urol"},{"key":"2406_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.12659\/MSM.897179","volume":"22","author":"QK Deng","year":"2016","unstructured":"Deng QK, Lei YG, Lin YL, Ma JG, Li WP (2016) Prognostic value of protocadherin10 (PCDH10) methylation in serum of prostate cancer patients. Med Sci Monit 22:516\u2013521","journal-title":"Med Sci Monit"},{"issue":"2","key":"2406_CR18","first-page":"471","volume":"151","author":"AP Soler","year":"1997","unstructured":"Soler AP, Harner GD, Knudsen KA, McBrearty FX, Grujic E, Salazar H, Han AC, Keshgegian AA (1997) Expression of P-cadherin identifies prostate-specific-antigen-negative cells in epithelial tissues of male sexual accessory organs and in prostatic carcinomas. Implications for prostate cancer biology. Am J Pathol 151(2):471\u2013478","journal-title":"Am J Pathol"},{"issue":"5","key":"2406_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/bcr309","volume":"3","author":"G Berx","year":"2001","unstructured":"Berx G, Van Roy F (2001) The E-cadherin\/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3(5):289\u2013293","journal-title":"Breast Cancer Res"},{"issue":"23","key":"2406_CR20","doi-asserted-by":"publisher","first-page":"7096","DOI":"10.1128\/MCB.00449-08","volume":"28","author":"YN Liu","year":"2008","unstructured":"Liu YN, Liu Y, Lee HJ, Hsu YH, Chen JH (2008) Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol 28(23):7096\u20137108. \n                    https:\/\/doi.org\/10.1128\/MCB.00449-08","journal-title":"Mol Cell Biol"},{"issue":"6","key":"2406_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s004280100516","volume":"439","author":"E Aken Van","year":"2001","unstructured":"Van Aken E, De Wever O, Correia da Rocha AS, Mareel M (2001) Defective E-cadherin\/catenin complexes in human cancer. Virchows Arch 439(6):725\u2013751","journal-title":"Virchows Arch"},{"issue":"6","key":"2406_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00428-009-0784-0","volume":"454","author":"M Mareel","year":"2009","unstructured":"Mareel M, Oliveira MJ, Madani I (2009) Cancer invasion and metastasis: interacting ecosystems. Virchows Arch 454(6):599\u2013622. \n                    https:\/\/doi.org\/10.1007\/s00428-009-0784-0","journal-title":"Virchows Arch"},{"issue":"10","key":"2406_CR23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3109\/07357900902769749","volume":"27","author":"N Makrilia","year":"2009","unstructured":"Makrilia N, Kollias A, Manolopoulos L, Syrigos K (2009) Cell adhesion molecules: role and clinical significance in cancer. Cancer Investig 27(10):1023\u20131037. \n                    https:\/\/doi.org\/10.3109\/07357900902769749","journal-title":"Cancer Investig"},{"issue":"1","key":"2406_CR24","first-page":"71","volume":"1","author":"KM Bae","year":"2011","unstructured":"Bae KM, Parker NN, Dai Y, Vieweg J, Siemann DW (2011) E-cadherin plasticity in prostate cancer stem cell invasion. Am J Cancer Res 1(1):71\u201384","journal-title":"Am J Cancer Res"},{"issue":"10","key":"2406_CR25","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-07-2938","volume":"68","author":"TT Onder","year":"2008","unstructured":"Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68(10):3645\u20133654. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2938","journal-title":"Cancer Res"},{"issue":"1","key":"2406_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000345057","volume":"90","author":"P Lazari","year":"2013","unstructured":"Lazari P, Poulias H, Gakiopoulou H, Thomopoulou GH, Barbatis C, Lazaris AC (2013) Differential immunohistochemical expression of CD44s, E-cadherin and \u03b2-catenin among hyperplastic and neoplastic lesions of the prostate gland. Urol Int 90(1):109\u2013116. \n                    https:\/\/doi.org\/10.1159\/000345057","journal-title":"Urol Int"},{"issue":"2","key":"2406_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/PAI.0b013e3181640bca","volume":"18","author":"J Pontes","year":"2010","unstructured":"Pontes J, Srougi M, Borra PM, Dall\u2019 Oglio MF, Ribeiro-Filho LA, Leite KR (2010) E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol 18(2):179\u2013184. \n                    https:\/\/doi.org\/10.1097\/PAI.0b013e3181640bca","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"2406_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10120-011-0004-x","volume":"14","author":"Y Uchikado","year":"2011","unstructured":"Uchikado Y, Okumura H, Ishigami S, Setoyama T, Matsumoto M, Owaki T, Kita Y, Natsugoe S (2011) Increased slug and decreased E-cadherin expression is related to poor prognosis in patients with gastric cancer. Gastric Cancer 14(1):41\u201349. \n                    https:\/\/doi.org\/10.1007\/s10120-011-0004-x","journal-title":"Gastric Cancer"},{"issue":"2","key":"2406_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.biocel.2008.09.027","volume":"41","author":"P Hulpiau","year":"2009","unstructured":"Hulpiau P, van Roy F (2009) Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol 41(2):349\u2013369. \n                    https:\/\/doi.org\/10.1016\/j.biocel.2008.09.027","journal-title":"Int J Biochem Cell Biol"},{"issue":"7\u20139","key":"2406_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1387\/ijdb.113382aa","volume":"55","author":"A Albergaria","year":"2011","unstructured":"Albergaria A, Ribeiro AS, Vieira AF, Sousa B, Nobre AR, Seruca R, Schmitt F, Paredes J (2011) P-cadherin role in normal breast development and cancer. Int J Dev Biol 55(7\u20139):811\u2013822. \n                    https:\/\/doi.org\/10.1387\/ijdb.113382aa","journal-title":"Int J Dev Biol"},{"key":"2406_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0448-4","volume":"14","author":"AF Vieira","year":"2015","unstructured":"Vieira AF, Paredes J (2015) P-cadherin and the journey to cancer metastasis. Mol Cancer 14:178. \n                    https:\/\/doi.org\/10.1186\/s12943-015-0448-4","journal-title":"Mol Cancer"},{"issue":"2","key":"2406_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, EAo U (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467\u2013479. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2013.11.002","journal-title":"Eur Urol"},{"key":"2406_CR33","unstructured":"Tang LH, Berlin J, Branton P, Burgart LJ, Carter DK, Compton CC, Fitzgibbons P, Frankel WL, Jessup J, Kakar S, Minsky B, Nakhleh R, Washington K (2013) Protocol for the examination of specimens from patients with carcinoma of the stomach. Gastrointestinal - Stomach, vol Stomach 3.2.0.1. College of American Pathologists (CAP). Based on AJCC\/UICC TNM, 7th edition. \n                    http:\/\/www.cap.org\/cancerprotocols\n                    \n                  . Accessed 1 Oct 2017"},{"issue":"1","key":"2406_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5146\/tjpath.2016.01392","volume":"1","author":"AE Abdelrahman","year":"2017","unstructured":"Abdelrahman AE, Arafa SA, Ahmed RA (2017) Prognostic value of Twist-1, E-cadherin and EZH2 in prostate Cancer: an Immunohistochemical study. Turk Patoloji Derg 1(1):198\u2013210. \n                    https:\/\/doi.org\/10.5146\/tjpath.2016.01392","journal-title":"Turk Patoloji Derg"},{"key":"2406_CR35","unstructured":"Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D, Chen H, Feuer E, Cronin K (2017) SEER Cancer Statistics Review, 1975\u20132014, National Cancer Institute. \n                    https:\/\/seer.cancer.gov\/csr\/1975_2014\/\n                    \n                  , based on November 2016 SEER data submission, posted to the SEER web site, April 2017. Bethesda, MD"},{"issue":"3","key":"2406_CR36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69(3):428\u2013435. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2015.06.046","journal-title":"Eur Urol"},{"issue":"10","key":"2406_CR37","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/bjc.2016.86","volume":"114","author":"DM Berney","year":"2016","unstructured":"Berney DM, Beltran L, Fisher G, North BV, Greenberg D, M\u00f8ller H, Soosay G, Scardino P, Cuzick J (2016) Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. Br J Cancer 114(10):1078\u20131083. \n                    https:\/\/doi.org\/10.1038\/bjc.2016.86","journal-title":"Br J Cancer"},{"issue":"29\u201330","key":"2406_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3238\/arztebl.2013.0497","volume":"110","author":"H Isbarn","year":"2013","unstructured":"Isbarn H, Huland H, Graefen M (2013) Results of radical prostatectomy in newly diagnosed prostate cancer: long-term survival rates in locally advanced and high-risk cancers. Dtsch Arztebl Int 110(29\u201330):497\u2013503. \n                    https:\/\/doi.org\/10.3238\/arztebl.2013.0497","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"2406_CR39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.eururo.2014.06.015","volume":"67","author":"BC Jeong","year":"2015","unstructured":"Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M (2015) The relationship between the extent of extraprostatic extension and survival following radical prostatectomy. Eur Urol 67(2):342\u2013346. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2014.06.015","journal-title":"Eur Urol"},{"issue":"15","key":"2406_CR40","first-page":"3189","volume":"57","author":"PJ Richmond","year":"1997","unstructured":"Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M (1997) Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 57(15):3189\u20133193","journal-title":"Cancer Res"},{"issue":"12","key":"2406_CR41","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/S0959-8049(01)00143-5","volume":"37","author":"S Loric","year":"2001","unstructured":"Loric S, Paradis V, Gala JL, Berteau P, Bedossa P, Benoit G, Eschw\u00e8ge P (2001) Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. Eur J Cancer 37(12):1475\u20131481","journal-title":"Eur J Cancer"},{"issue":"13","key":"2406_CR42","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/pros.20626","volume":"67","author":"IM Oort van","year":"2007","unstructured":"van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, Witjes JA, Schalken JA (2007) The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate 67(13):1432\u20131438. \n                    https:\/\/doi.org\/10.1002\/pros.20626","journal-title":"Prostate"},{"issue":"1","key":"2406_CR43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1464-410X.2012.11551.x","volume":"111","author":"HM Behnsawy","year":"2013","unstructured":"Behnsawy HM, Miyake H, Harada K, Fujisawa M (2013) Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int 111(1):30\u201337. \n                    https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11551.x","journal-title":"BJU Int"},{"issue":"2","key":"2406_CR44","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.yexmp.2013.07.010","volume":"95","author":"H Whiteland","year":"2013","unstructured":"Whiteland H, Spencer-Harty S, Thomas DH, Davies C, Morgan C, Kynaston H, Bose P, Fenn N, Lewis PD, Bodger O, Jenkins S, Doak SH (2013) Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer. Exp Mol Pathol 95(2):220\u2013226. \n                    https:\/\/doi.org\/10.1016\/j.yexmp.2013.07.010","journal-title":"Exp Mol Pathol"},{"issue":"4","key":"2406_CR45","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.3892\/ol.2015.3556","volume":"10","author":"D Ma","year":"2015","unstructured":"Ma D, Zhou Z, Yang B, He Q, Zhang Q, Zhang XH (2015) Association of molecular biomarkers expression with biochemical recurrence in prostate cancer through tissue microarray immunostaining. Oncol Lett 10(4):2185\u20132191. \n                    https:\/\/doi.org\/10.3892\/ol.2015.3556","journal-title":"Oncol Lett"},{"issue":"2","key":"2406_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.bbcan.2012.05.002","volume":"1826","author":"J Paredes","year":"2012","unstructured":"Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa AM, Sim\u00f5es-Correia J, Oliveira MJ, Pinheiro H, Pinho SS, Mateus R, Reis CA, Leite M, Fernandes MS, Schmitt F, Carneiro F, Figueiredo C, Oliveira C, Seruca R (2012) Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta 1826(2):297\u2013311. \n                    https:\/\/doi.org\/10.1016\/j.bbcan.2012.05.002","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"2406_CR47","first-page":"2916","volume":"52","author":"MJ Bussemakers","year":"1992","unstructured":"Bussemakers MJ, van Moorselaar RJ, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FM, Schalken JA (1992) Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 52(10):2916\u20132922","journal-title":"Cancer Res"},{"issue":"14","key":"2406_CR48","first-page":"3929","volume":"54","author":"R Umbas","year":"1994","unstructured":"Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA (1994) Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54(14):3929\u20133933","journal-title":"Cancer Res"},{"issue":"11","key":"2406_CR49","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1023\/A:1004111331752","volume":"32","author":"MI Arenas","year":"2000","unstructured":"Arenas MI, Romo E, Royuela M, Fraile B, Paniagua R (2000) E-, N- and P-cadherin, and alpha-, beta- and gamma-catenin protein expression in normal, hyperplastic and carcinomatous human prostate. Histochem J 32(11):659\u2013667","journal-title":"Histochem J"},{"issue":"23","key":"2406_CR50","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-07-1263","volume":"13","author":"K Gravdal","year":"2007","unstructured":"Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2007) A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 13(23):7003\u20137011. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1263","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2406_CR51","first-page":"2121","volume":"3","author":"DF Jarrard","year":"1997","unstructured":"Jarrard DF, Paul R, van Bokhoven A, Nguyen SH, Bova GS, Wheelock MJ, Johnson KR, Schalken J, Bussemakers M, Isaacs WB (1997) P-cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer. Clin Cancer Res 3(11):2121\u20132128","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2406_CR52","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/bcr1774","volume":"9","author":"J Paredes","year":"2007","unstructured":"Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC (2007) P-cadherin expression in breast cancer: a review. Breast Cancer Res 9(5):214. \n                    https:\/\/doi.org\/10.1186\/bcr1774","journal-title":"Breast Cancer Res"},{"issue":"20","key":"2406_CR53","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-08-1086","volume":"14","author":"K Imai","year":"2008","unstructured":"Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y (2008) Identification of a novel tumor-associated antigen, cadherin 3\/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 14(20):6487\u20136495. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1086","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2406_CR54","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc3447","volume":"13","author":"B Craene De","year":"2013","unstructured":"De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13(2):97\u2013110. \n                    https:\/\/doi.org\/10.1038\/nrc3447","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2406_CR55","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871\u2013890. \n                    https:\/\/doi.org\/10.1016\/j.cell.2009.11.007","journal-title":"Cell"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-018-2406-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2406-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2406-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T15:36:55Z","timestamp":1568993815000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-018-2406-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,13]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["2406"],"URL":"https:\/\/doi.org\/10.1007\/s00428-018-2406-1","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,13]]},"assertion":[{"value":"23 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional ethics committee of Portuguese Oncology Institute Porto (Comiss\u00e3o de \u00c9tica para a Sa\u00fade do IPO Porto\u2014CES 235\/2017).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}